2021-07-30T08:51:02-05:00 2020-12-31 WITHUMSMITHBROWNPC 4600 EAST WEST HWY 900 BETHESDA MD 208143423 990 2020-01-01 042531031 NATIONAL FOUNDATION FOR CANCER RESEARCH % KWOK LEUNG NATI 3016541250 5515 SECURITY LANE 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT & CEO 3016541250 2021-07-26 true SUJUAN BA 999009999 Richard Ruvelson P00234075 3012726000 2021-07-26 3 2020 2022-09-23 18:48:47Z SUJUAN BA 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 12496073 false 5582 X WWW.NFCR.ORG X 1973 MA TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER. 5 5 27 20 2906 1434 9878471 10990906 0 0 769613 271161 289821 203223 10937905 11465290 6224339 4301016 0 0 2882141 2652256 64945 66290 1743501 5360949 3810439 14532374 10830001 -3594469 635289 10554744 12283856 3025275 3362374 7529469 8921482 X SEE SCHEDULE O false false 5776093 4301016 CANCER RESEARCH - SEE SCHEDULE O 2503029 CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O 8279122 true true false false false true false false false true true true false true true true false true false false false false true true true false false true true true false false false false false false true false true false false false false true true false false false true 27 0 true 27 true true true false false false false true true false false false false false false false false false X 5 5 false false false false false false false true true false true true true true true true true true true true false AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MS NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WI X X KWOK LEUNG 3016541250 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 SUJUAN BA PRESIDENT/CEO 40.0 2.0 X 342741 0 75217 FRANKLIN C SALISBURY JR CEO EMERITUS (THRU 8/2020) 40.0 0.5 X 231254 0 50446 YI WANG CHIEF STRTGY OFF. - ALLIANCES 40.0 1.0 X 209593 0 28875 KWOK LEUNG CFO/SECRETARY 40.0 5.0 X 186688 0 28628 BRIAN WACHTEL EXECUTIVE DIRECTOR 40.0 0.0 X 126180 0 16783 BRADLEY GILLENWATER SR. DIR. FOR CORP. OUTREACH 40.0 0.0 X 111681 0 21108 JUDITH P BARNHARD CHAIR 3.0 0.0 X X 0 0 0 WENDI P DENNARD TREASURER 1.5 0.0 X X 0 0 0 JOSEPH F FRANLIN DIRECTOR (THRU 7/2020) 1.5 0.0 X 0 0 0 PADMAKUMAR KAIMAL DIRECTOR (EFF 4/2020) 1.5 0.0 X 0 0 0 GUS KODERSHA DIRECTOR (THRU 10/2020) 1.5 0.0 X 0 0 0 WILLIAM SCANDONE DIRECTOR (THRU 6/2020) 1.5 0.0 X 0 0 0 ALFRED SLANETZ DIRECTOR (EFF 7/2020) 1.5 0.0 X 0 0 0 EDWARD S WEST DIRECTOR 1.5 0.0 X 0 0 0 1208137 0 221057 6 false true false CP DIRECT INC 4600 A BOSTON WAY LANHAM MD 20706 PRINTING SERVICES 298550 REDFIELD DIRECT LLC 11422 MIRACLE HILLS DRIVE 450 OMAHA NE 68154 LABEL PRINTING 293490 CALMARK GROUP LLC 6755 S SAYRE AVENUE BEDFORD PARK IL 60638 MAILSHOP 291536 MERKLE 7001 COLUMBIA GATEWAY DRIVE COLUMBIA MD 21046 CONSULTING 218790 MACKAY MITCHELL ENVELOPE CO 2100 ELM STREET SE MINNEAPOLIS MN 55414 ENVELOPE PRINTING 142497 5 42975 208160 10000 10729771 112890 10990906 0 206471 206471 0 15973 15973 0 0 0 1065114 1000424 64690 64690 64690 22386 208160 30359 -7973 -7973 0 0 0 0 0 0 MAILING LIST RENTALS 541800 195223 2906 192317 195223 11465290 2906 471478 4079482 4079482 211534 211534 10000 10000 0 633275 452663 171050 9562 0 1625296 1228250 194312 202734 175458 133094 17850 24514 88717 52449 27082 9186 129510 96129 20814 12567 0 9044 437 8607 51280 51280 0 66290 66290 36839 36839 239401 112759 122481 4161 31785 997 27239 3549 121832 48081 46191 27560 450394 274555 4511 171328 0 224537 166410 35494 22633 13878 4966 8912 0 0 0 0 37749 27976 5976 3797 30425 22548 4836 3041 DIRECT MAIL PROGRAMS 2429912 1300167 1129745 LOCK BOX SERVICE 76167 44310 31857 PROCESS FEES-LIST SALES 21523 12315 9208 MISCELLANEOUS FUNDRAISING 33928 22159 11769 1745 1745 10830001 8279122 807378 1743501 X 2873445 1709239 1164206 1000 3062 1530154 2123510 0 0 201229 70919 0 0 0 0 0 0 0 0 337322 180076 393083 325850 99720 67233 4349076 5041532 442 750441 0 0 0 0 4035801 4047083 10554744 12283856 929618 878399 577279 743885 135 135 0 0 0 0 0 0 0 0 0 400000 1518243 1339955 3025275 3362374 X 4057468 5008076 3472001 3913406 7529469 8921482 10554744 12283856 635289 756724 X false true X true false X 13952247 11921451 12714798 9898471 10990906 59477873 0 0 13952247 11921451 12714798 9898471 10990906 59477873 84785 59393088 287499 296562 308859 270568 222444 1385932 9182 647 9829 348604 284518 259968 301733 192317 1387140 62260774 0.95394 0.95255 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 1 3040 true true 7915837 3260266 193223 3584588 7784738 10396983 4136982 286710 6904838 7915837 8699102 7119860 -271815 5150164 10396983 8164316 3394266 213282 3072762 8699102 7627682 3687809 22308 3173483 8164316 0.47610 0.30320 0.22070 false false 26890 8714 18176 219808 185470 34338 146385 131666 14719 67233 0 AMOUNT HELD IN TRUST BY OTHERS 2819864 RIGHT OF USE ASSET 1227219 4047083 0 LEASE LIABILITY 1339955 1339955 X 12185930 756724 2500 759224 11426706 36839 1745 38584 11465290 10793917 2500 2500 10791417 36839 1745 38584 10830001 PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS: THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS. PART X, LINE 2 - FIN 48 FOOTNOTE: Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2020 there are no uncertain positions taken or expected to be taken that would require recognition in the consolidated financial statements. The NFCR and affiliates are subject to routine audits by taxing jurisdictions; however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for the periods presented in these consolidated financial statements. Should such penalties and interest be incurred, the Foundation's policy is to recognize them as general and administrative expenses on the consolidated statements of activities. PART XI, LINE 4B - OTHER REVENUES INCLUDED ON FORM 990 BUT NOT FINANCIALS: $1,745 FOREIGN TAXES WITHHOLDING ON INVESTMENT INCOME DEDUCTED FROM REVENUES ON FINANCIAL STATEMENTS PART XII, LINE 4B -OTHER EXPENSES INCLUDED ON FORM 990 BUT NOT FINANCIALS: $1,745 FOREIGN TAXES W/H ON INVESTMENT INCOME RESEARCH REVIEW Europe (Including Iceland and Greenland) 1 5000 CHECK RESEARCH REVIEW East Asia and the Pacific 1 5000 CHECK false false false false false false X X X X X X X true MERKLE INC 7001 COLUMBIA GATEWAY DRIVE COLUMBIA MD 21046 DIRECT MAIL COUNSEL false 6845951 66290 6779661 6845951 66290 6779661 AL AK AZ AR CA CO CT DC FL GA HI IL IN KS KY ME MD MA MI MN MO NH NJ NM NY NC ND OH OK OR PA RI SC TN UT VA WA WV WY DAFFODILS 89636 67250 22386 16530 6000 2151 PLAY 4 THE CURE 120955 120955 5529 5 19955 19955 149 230546 208160 22386 16530 6000 7829 30359 -7973 true ALBERT EINSTEIN COLLEGE OF MEDICINE 1300 MORRIS PARK AVE BRONX NY 10461 472209056 501(c)(3) 17171 RESEARCH CONTRACTS MASSACHUSETTS GENERAL HOSPITAL PO BOX 414876 BOSTON MA 02241 041564655 501(c)(3) 200000 4987 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES RD LA JOLLA CA 92037 330435954 501(c)(3) 100000 RESEARCH CONTRACTS VIRGINIA COMMONWEALTH UNIVERSITY PO BOX 980568 RICHMOND VA 23298 546001758 501(C)(3) 100000 17500 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS KUMC RESEARCH INSTITUTE INC 3901 RAINBOW BLVD MAIL STOP 1039 KANSAS CITY KS 66103 481108830 501(c)(3) 75000 20700 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS UNIVERSITY OF PENNSYLVANIA 3451 WALNUT ST PHILADELPHIA PA 19104 231352685 501(C)(3) 104458 RESEARCH CONTRACTS SCOTTSDALE HEALTHCARE CORP 8125 N HAYDEN RD SCOTTSDALE AZ 85258 942735850 501(C)(3) 37010 CANCER HOTLINE WAKE FOREST UNIVERSITY HEALTH SCIENCES MEDICAL CENTER BLVD WINSTONSALEM NC 27157 223849199 501(C)(3) 75000 60000 FMV CHEMICALS & MATERIAL RESEARCH CONTRACTS GLOBAL COALITION FOR ADAPTIVE RESEARCH INC PO BOX 427 LEXINGTON MA 02420 821199380 501(C)(3) 500000 RESEARCH CONTRACTS AIM HI ACCELERATOR FUND 5515 SECURITY LN 1105 ROCKVILLE MD 20852 824322538 501(C)(3) 2337832 BOOK VALUE SECURITIES TRANSLATIONAL ANGELINK 16192 COASTAL HIGHWAY LEWES DE 19958 50000 TRANSLATIONAL 10 1 CANCER RESEARCH 5 146534 RESEARCH REVIEW 4 65000 PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA: GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR. X X X X X false false false false false false false false false SUJUAN BA PRESIDENT/CEO 341967 0 774 53000 0 22217 0 417958 0 0 0 FRANKLIN C SALISBURY JR CEO EMERITUS (THRU 8/2020) 229730 0 1524 33252 0 17194 0 281700 0 0 0 YI WANG CHIEF STRTGY OFF. - ALLIANCES 208405 0 1188 27143 0 1732 0 238468 0 0 0 KWOK LEUNG CFO/SECRETARY 185500 0 1188 27825 0 803 0 215316 0 0 0 FRANKLIN C SALISBURY JR SPOUSE OF SUJUAN BA, PRESIDENT & CEO 231254 WAGE COMPENSATION false X 4 12203 stock market value X CHEMICALS & MATERIALS 4 100687 FMV false true false PART III, LINE 1 - ORGANIZATION'S MISSION: The National Foundation for Cancer Research (NFCR) is a leading public charity dedicated to funding cancer research and public education relating to cancer prevention, earlier diagnosis, better treatments and, ultimately, cures for cancer. NFCR has distinguished itself in the cancer research sector by emphasizing long-term, transformative research often overlooked by other major funding sources. NFCR promotes and facilitates collaboration among scientists to accelerate the pace of discovery from bench to bedside. Since 1973, NFCR has provided more than $390 million in support of discovery-oriented cancer research focused on understanding how and why cells become cancerous, and on public education relating to cancer prevention, detection, and treatment. NFCR is committed to fighting cancer by funding high-risk, high-impact, and potentially high-reward discoveries in the labs and transforming them into life-saving treatments for cancer patients. Through global collaboration, NFCR is making unique impacts on new, accelerated paths to a cure. NFCR envisions a world without cancer! NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT FROM OUR DONORS. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG. PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS: HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ============================================ With support from our generous donors, NFCR-funded scientists have made numerous remarkable advances in the fight against cancer. Their research encompasses a wide variety of fields, many of which could ultimately lead TO a cure for this deadly disease. Racial Disparity Research in Lung Cancer ===================================================================== Wei Zhang, Ph.D. found African American lung cancer patients have different mutations in key cancer-related genes than Caucasian patients, contributing to the increased incidence and lower survival rates in African Americans. The Zhang team won a larger national grant to study more patients, which may lead to life-saving treatments to reduce racial disparity in lung cancer survival rates. Predicting Why Cancer Spreads in Some Patients ====================================================================== Danny Welch, Ph.D. is finding variabilities in the cell part that produces our body's energy, possibly explaining why cancer spreads in some patients but not in others. This may partially explain racial disparities in cancer rates and severity. His team's research suggests a simple blood test could guide doctors to aggressively treat patients whose cancer may spread, or spare patients at low risk from undergoing treatment side effects. Propelling Development of a New Immunotherapy ======================================================================= With NFCR discovery research funds, Paul Fisher, M.Ph., Ph.D. advanced his powerful immune-stimulating agent as a new treatment to stop the spread of different types of cancer. NFCR's AIM-HI Translational Research Initiative awarded additional support to bridge the gap between discovery research and expensive clinical drug development required for FDA approval. This year, the AIM-HI funds were matched from another non-profit. Together, we are propelling research forward and giving patients hope for a cure. Halting Spread of Pancreatic Cancer ===================================================================== Daniel A. Haber, M.D., Ph.D. identified a pancreatic cancer gene that drives cancer cells to spread. Scientists have not had much success identifying genes and treatments to stop spreading cells even in early stages of pancreatic cancer. His team's discovery will launch the development of effective therapies for patients with pancreatic cancer and many other cancers. Botanical Drug Reaches Patients in Clinical Trials ============================================================== Over two decades of funding from NFCR supporters helped Yung-Chi Cheng, Ph.D. and his team develop YIV-906, a botanical drug with multiple anti-cancer properties that enhance immunotherapy and chemotherapy. NFCR's AIM-HI Translational Research Initiative support facilitated the translation of YIV-906 to reach the clinical stages. Now, a global clinical trial is treating liver cancer patients with YIV-906 combined with a frontline drug. Since YIV-906 also protects the gastrointestinal tract from harsh side effects of many therapies, the botanical should alleviate adverse effects of the frontline drug that has caused many patients to discontinue its use. With success in final phase clinical trials, YIV-906 could become the first U.S. approved botanical cancer drug - a remarkable achievement. Unique Clinical Trial Gives Hope to Brain Cancer Patients ============================================================ A revolutionary clinical trial model, GBM AGILE, is now available to treat patients with the deadliest brain cancer, glioblastoma (GBM). Patients who have not had a new effective treatment in decades, now have hope for survival. GBM AGILE's unique design surpasses standard trials to efficiently evaluate multiple new drugs and drug combinations simultaneously. Benefits include lower cost, reduced time, and fewer patients required to evaluate potential new therapies. Two more experimental therapies will soon be available for a total of three experimental "treatment arms". In 2020, 31 U.S. cancer centers were open to treat patients with more than 40 trial sites opening soon in the U.S. and Canada. Trial expansion in Europe and China is underway. To date, over 300 patients have already been screened for trial eligibility, a much higher rate than expected. NFCR has been a pioneer and founding supporter of GBM AGILE. We are also a strategic partner of the Global Coalition for Adaptive Research (GCAR), the official nonprofit sponsor of GBM AGILE. This uniquely designed clinical trial platform is now being utilized to rapidly test new treatments COVID-19 and in the future for other cancers. Supporting the Fight Against Childhood Cancer ============================================= Cancer can damage the eye's retina and cause blindness. With your support, NFCR is now funding the pioneering research of ophthalmologists, Dr. Jean Bennett and Dr. Katherine Uyhazi. Dr. Bennett developed the first FDA-approved gene therapy for a genetic disease, restoring retinal genes and vision in childhood blindness! Together, Drs. Bennett and Uyhazi will now use both gene and cell replacement therapy, two necessities to restore critical retinal components damaged in eye cancer. Your support will impact eye cancer patients as well as those with other eye diseases, giving new hope that their sight may be saved. New Treatment for Childhood Cancer =========================================================== Lack of therapies made specifically for young patients forces pediatric oncologists to use adult cancer drugs. In addition to debilitating side effects that can last a lifetime, there are many forms of childhood cancer whose outlook is poor. Unfortunately, financial investment to develop specific pediatric cancer drugs has been dismal. NFCR's AIM-HI Translational Research Initiative supports a pipeline to develop treatments for the most common pediatric cancers with the worst outcome. Volasertib is the pipeline's first drug and will soon reach clinical trials to treat rhabdomyosarcoma, a rare and deadly childhood cancer affecting 450 new patients yearly. In 2020, the FDA granted Rare Pediatric Disease Designation to volasertib which will fast-track the drug approval process. The FDA also awarded volasertib the Orphan Drug Designation (for diseases that affect less than 200,000 individuals) that provides tax credits to reduce clinical trial costs and a waiver of new drug application fees, saving developers of volasertib nearly $2.9 million dollars in 2020. These benefits will save precious time and money for patients, doctors and drug developers. Your commitment to funding this unmet medical need for better treatments is making a difference in the lives of children! NFCR'S CANCER PATIENT TREATMENT ASSISTANCE =================================================== A cancer diagnosis comes with panic, confusion, uncertainty and questions: What tests should be scheduled, What are the best treatment options, AND ARE THERE CLINICAL TRIALS FOR A NEW THERAPY THAT ARE SUITABLE TO THE PATIENT'S CANCER. NFCR understands the patient's frustrations and needs, and we provide assistance through the difficult time by linking a person in need with the Cancer Patient Treatment Assistance, where one may receive expert professional help from our oncologists. - Understanding the diagnosis and treatment options - Recommend top oncologists to meet specific needs and coordinate the referral process - Identify clinical trials of the newest therapies for advanced cancer or rare tumors for which no standard care or effective therapy is available This medical advice is provided as a resource for patients to consult with their medical team. PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC: NFCR provides the public with free materials containing valuable information on the most up-to-date cancer preventive measures, treatment options, and diagnostic tools. Our powerful message has been mailed annually to households, reaching over 266,000 email subscribers and tens of thousands of individuals through our social media channels (Twitter and Facebook) and through our website and blogs, helps to assure that fewer of today's healthy individuals will get cancer and more of today's cancer patients will become tomorrow's cancer survivors. Our public education materials include early cancer detection guide, cancer prevention kits, recipes for healthy living, electronic and printed newsletters, the latest cancer headlines, and in-depth online cancer information. PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990: THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENCE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEADLINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMBERS' REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN, IF NECESSARY, WILL BE FILED. PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE: EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY. PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION: ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION. PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S: THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE. PART IX, LINE 26, JOINT COSTS ALLOCATION: NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY POSTAL MAIL, EMAIL, PHONE, WEBSITE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT ABOUT CANCER AND UPHOLD ITS MISSION, AND AT THE SAME TIME TO PROVIDE FUNDRAISING OPPORTUNITIES. THE COSTS RELATED TO THESE JOINT ACTIVITIES ARE ALLOCATED, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING. DARWIN FOUNDATION 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 371473821 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true RESEARCH FOR A CURE 5515 SECURITY LANE SUITE 1105 ROCKVILLE MD 20852 010744146 CANCER RESEAR DC 501(C)3 509(A)(3) NFCR true false false false false false false false false false false false false false false false false false false false